4-羟基查尔酮通过靶向表皮生长因子受体/蛋白激酶B/细胞外信号调节激酶1/2信号通路抑制人冠状病毒HCoV-OC43
4-Hydroxychalcone Inhibits Human Coronavirus HCoV-OC43 by Targeting EGFR/AKT/ERK1/2 Signaling Pathway.
作者信息
Huang Yuanyuan, Li Jieyu, Luo Qiting, Dai Yuexiang, Luo Xinyi, Xu Jiapeng, Ye Wei, Zhou Xinrui, Diao Jiayi, Ren Zhe, Liu Ge, He Zhendan, Wang Zhiping, Wang Yifei, Zhu Qinchang
机构信息
School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China.
College of Pharmacy, Shenzhen Technology University, Shenzhen 518118, China.
出版信息
Viruses. 2025 Jul 23;17(8):1028. doi: 10.3390/v17081028.
Human coronaviruses are a group of viruses that continue to threaten human health. In this study, we investigated the antiviral activity of 4-hydroxychalcone (4HCH), a chalcone derivative, against human coronavirus HCoV-OC43. We found that 4HCH significantly inhibited the cytopathic effect, reduced viral protein and RNA levels in infected cells, and increased the survival rate of HCoV-OC43-infected suckling mice. Mechanistically, 4HCH targets the early stages of viral infection by binding to the epidermal growth factor receptor (EGFR) and inhibiting the EGFR/AKT/ERK1/2 signaling pathway, thereby suppressing viral replication. Additionally, 4HCH significantly reduced the production of pro-inflammatory cytokines and chemokines in both HCoV-OC43-infected RD cells and a suckling mouse model. Our findings demonstrate that 4HCH exhibits potent antiviral activity both in vitro and in vivo, suggesting its potential as a therapeutic agent against human coronaviruses. This study highlights EGFR as a promising host target for antiviral drug development and positions 4HCH as a candidate for further investigation in the treatment of coronavirus infections.
人冠状病毒是一类持续威胁人类健康的病毒。在本研究中,我们调查了查尔酮衍生物4-羟基查尔酮(4HCH)对人冠状病毒HCoV-OC43的抗病毒活性。我们发现,4HCH显著抑制细胞病变效应,降低感染细胞中的病毒蛋白和RNA水平,并提高HCoV-OC43感染的乳鼠存活率。机制上,4HCH通过与表皮生长因子受体(EGFR)结合并抑制EGFR/AKT/ERK1/2信号通路靶向病毒感染的早期阶段,从而抑制病毒复制。此外,4HCH显著降低了HCoV-OC43感染的RD细胞和乳鼠模型中促炎细胞因子和趋化因子的产生。我们的研究结果表明,4HCH在体外和体内均表现出强大的抗病毒活性,表明其作为抗人冠状病毒治疗剂的潜力。本研究强调EGFR作为抗病毒药物开发的一个有前景的宿主靶点,并将4HCH定位为进一步研究冠状病毒感染治疗的候选药物。